Rare Protocols

Breast

Protocol EAY191 - N2
Cancer Type: Rare Cancer

PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1

Please check out the rare protocol list to locate other studies within this disease site.

Endocrine/Neuroendocrine

Protocol Alliance A021804
Cancer Type: ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S2012
Cancer Type: RARE

RANDOMIZED PHASE II/III TRIAL OF FIRST LINE PLATINUM/ETOPOSIDE WITH OR WITHOUT
ATEZOLIZUMAB (NSC#783608) IN PATIENTS WITH POORLY DIFFERENTIATED
EXTRAPULMONARY SMALL CELL NEUROENDOCRINE CARCINOMAS (NEC)

Please check out the rare protocol list to locate other studies within this disease site.

Gastrointestinal

Protocol SWOG S1922
Cancer Type: Small bowel Adenocarcinoma

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAY191 - A6
Cancer Type: Rare Cancer

A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS

Please check out the rare protocol list to locate other studies within this disease site.

Genitourinary

Please check out the rare protocol list to locate other studies within this disease site.

Gynecologic

Protocol EAY191 - N4
Cancer Type: Rare Cancer

A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB
OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR
PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL
CANCERS

Please check out the rare protocol list to locate other studies within this disease site.

Head and Neck

Protocol NRG HN010
Cancer Type: RARE

A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER

Please check out the rare protocol list to locate other studies within this disease site.

Lung

Protocol Alliance A092001
Cancer Type: RARE

PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA

Please check out the rare protocol list to locate other studies within this disease site.

Multisite

Protocol EAY191 - S3
Cancer Type: Rare Cancer

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory
Participants with AKT-Altered Advanced Non-Breast Solid Tumors

Protocol EAY191 - A3
Cancer Type: Rare Cancer
Fast Facts

A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS

Please check out the rare protocol list to locate other studies within this disease site.

Rare

Protocol EAY191 - A3
Cancer Type: Rare Cancer
Fast Facts

A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAY191 - N2
Cancer Type: Rare Cancer

PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAY191 - N4
Cancer Type: Rare Cancer

A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB
OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR
PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL
CANCERS

Protocol EAY191 - S3
Cancer Type: Rare Cancer

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory
Participants with AKT-Altered Advanced Non-Breast Solid Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A021804
Cancer Type: ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Protocol SWOG S2012
Cancer Type: RARE

RANDOMIZED PHASE II/III TRIAL OF FIRST LINE PLATINUM/ETOPOSIDE WITH OR WITHOUT
ATEZOLIZUMAB (NSC#783608) IN PATIENTS WITH POORLY DIFFERENTIATED
EXTRAPULMONARY SMALL CELL NEUROENDOCRINE CARCINOMAS (NEC)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAY191 - E5
Cancer Type: Rare Cancer

A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1922
Cancer Type: Small bowel Adenocarcinoma

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Protocol EAY191 - A6
Cancer Type: Rare Cancer

A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS

Please check out the rare protocol list to locate other studies within this disease site.

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG HN010
Cancer Type: RARE

A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A092001
Cancer Type: RARE

PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA

Protocol SWOG S1900K
Cancer Type: Rare Cancer

A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

Protocol SWOG S1900G
Cancer Type: Rare Cancer

A Randomized Phase II Study of Capmatinib Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.